Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITAS-309 phase 3 trial of itacitinib plus corticosteroids for first-line chronic graft-versus-host disease
MOH_2019-06-17_005993Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of itacitinib in chronic graft-versus-host disease (cGVHD) (4 arms), sponsored by Incyte. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
itacitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2019-06-17_005993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-17_005993.